AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Gossamer Bio, Inc. posted a Q1 2026 primary and diluted lack of $0.20 per share, wider than the anticipated lack of $0.17 and marking a 25.0% improve from the $0.16 loss recorded in Q1 2025. The clinical-stage biopharmaceutical firm, which focuses on growing seralutinib for pulmonary hypertension and pulmonary arterial hypertension, reported a internet lack of $46.7M for the quarter.
Income totaled $17.0M for the quarter, up 71.5% from $9.9M in Q1 2025. The robust income progress comes as the corporate advances its pipeline of therapies focusing on critical cardiovascular and inflammatory situations. Money, money equivalents and marketable securities was $99 million for the quarter.
Wall Road stays divided on the corporate’s prospects, with consensus standing at 6 purchase, 6 maintain, and 1 promote suggestions. The widening losses mirror the capital-intensive nature of medical improvement as Gossamer works to convey seralutinib by way of late-stage trials and towards potential commercialization within the pulmonary hypertension house.
An in depth evaluation of Gossamer Bio, Inc.’s quarter follows shortly on AlphaStreet.
This content material is for informational functions solely and shouldn’t be thought-about funding recommendation. AlphaStreet Intelligence analyzes monetary knowledge utilizing AI to ship quick and correct market data. Human editors confirm content material.
